Boston Scientific expanded the recall of its Taxus drug-coated stents from an initial 200 to 85,000 because of problems that occur during the implant procedure, but said patients who have already had stents successfully implanted should not be concerned. Several hospitals said they are suspending use of the stent until assured the problems have been corrected. The firm also said it would delay release of second-quarter results and probably faces a $45 million reduction in sales and a $50 million write-off of inventory.

Related Summaries